« Back
Home /
UBX1325

UBX1325

Item no.	HY-150069-5mg
Manufacturer	MedChem Express
CASRN	2271269-01-1
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.16
Citations	[1]Pamela Tsuruda, et al. UBX1325, a small molecule inhibitor of Bcl-xL, attenuates vascular dysfunction in two animal models of retinopathy. Investigative Ophthalmology & Visual Science June 2021,Volume 62, Issue 8
Smiles	CC1=C(C(C2=CC=CC(N3CCN(CC3)C4=CC=C(C=C4)NS(=O)(C5=CC=C(C(S(=O)(C(F)(F)F)=O)=C5)N[C@@H](CSC6=CC=CC=C6)CCN7CCC(CC7)OP(O)(O)=O)=O)=C2)=C(N1C(C)C)C8=CC=C(C=C8)Cl)C(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	Apoptosis; Bcl-2 Family
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture)
Molecular Weight	1159.69
Product Description	UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR)[1].
Manufacturer - Research Area	Metabolic Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-150069-5mg-safety-datasheet.pdf